ARTICLE | Distillery Therapeutics
Neurology
January 3, 2017 11:03 PM UTC
In vitro and mouse studies suggest locked nucleic acid (LNA) antisense oligonucleotides targeting CTG repeats in mutant HTT (LNA-CTG) could help treat HD. In human fibroblasts from HD patients, LNA-CT...
BCIQ Target Profiles